Clinical utility of secukinumab in moderate-to-severe scalp psoriasis: evidence to date
Dario Kivelevitch,1 Sima Amin,2 Alan Menter11Baylor University Medical Center, Dallas, TX, USA; 2Texas A&M College of Medicine, Bryan, TX, USAAbstract: Psoriasis is an immune-mediated inflammatory dermatosis commonly affecting the scalp and fringes of the face, neck and ears. It may be difficult...
Saved in:
Main Authors: | Kivelevitch D (Author), Amin S (Author), Menter A (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2019-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
IL-23 Inhibitors for Moderate-to-Severe Plaque Psoriasis: A Review of Clinical Efficacy, Safety, and Tolerability
by: Sima D. Amin, et al.
Published: (2019) -
Profile of tildrakizumab-asmn in the treatment of moderate-to-severe plaque psoriasis: evidence to date
by: Beck KM, et al.
Published: (2018) -
Treatment of Psoriasis with Secukinumab in Challenging Patient Scenarios: A Review of the Available Evidence
by: Jashin J. Wu, et al.
Published: (2020) -
Treatment challenges in the management of moderate-to-severe plaque psoriasis – role of secukinumab
by: Malakouti M, et al.
Published: (2016) -
Correction to: Treatment of Psoriasis with Secukinumab in Challenging Patient Scenarios: A Review of the Available Evidence
by: Jashin J. Wu, et al.
Published: (2020)